Gael Touya

President of Aptar Pharma, Aptargroup

Search every verified Gael Touya interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Gael Touya, President of Aptar Pharma at Aptargroup, has been discussing the company's performance and market conditions in recent interviews. Touya stated that the company's numbers reflect inventory adjustments following the COVID-19 pandemic, noting that while consumer demand remains, growth rates in fragrance and other segments have slowed from pandemic-era highs. He described tariffs as "neutral" for AptarGroup, citing the company's philosophy of serving regions from within the region)Skip. Touya also noted that the Chinese market has not seen the vigorous rebound some expected, but that Chinese brands are supplying the market and Asia remains a positive region for the company. Touya highlighted strong demand in the pharmaceutical sector, particularly for nasal sprays, inhalers, and sinus rinses, and said the company has invested over $180 million in capacity for biologic drugs including GLP-1 drugs. He identified weakness in the U.S. food and personal care home care segments, attributing it to changing consumer patterns and retailers working down COVID inventories. Touya noted that labor force issues have abated)Skip, and that the company's business is 75% outside the U.S., with travel retail driving growth in beauty and high-end fragrances. He described China as an important market and said the company is not in geopolitically sensitive areas.